Search

Displaying results 4821 - 4830 of 10000 in total
  1. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), exhibited low toxicity and significant anticancer activity in vitro and in vivo. … than BA in preclinical studies.

    Synonyms: AN-9
  2. Drug

    Sodium phosphate, monobasic, unspecified form

    go.drugbank.com/drugs/DB14503
    Approved

    Mixtures: Utira-C, gent-L-tip
  3. Drug

    AOD9604

    go.drugbank.com/drugs/DB06388
    Experimental

    AOD9604 is a synthetic analogue of the lipolytic domain of human growth hormone, being investigated for the treatment of obesity.

    Synonyms: L-PHENYLALANINE, L-TYROSYL-L-LEUCYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-GLUTAMINYL-L-CYSTEINYL-L-ARGINYL-L-SERYL-L-VALYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-SERYL-L-CYSTEINYLGLYCYL-, CYCLIC (7->14)-DISULFIDE, TYR-LEU-ARG-ILE-VAL-GLN-CYS-ARG-SER-VAL-GLU-GLY-SER-CYS-GLY-PHE CYCLIC (7->14)-DISULFIDE
  4. Drug

    Diodone

    go.drugbank.com/drugs/DB13568
    Experimental

    Categories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-Ring
  5. Drug

    Icotinib

    go.drugbank.com/drugs/DB11737
    Investigational

    Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc … . was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inducers
  6. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. … ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself.

  7. Drug

    NNZ-2591

    go.drugbank.com/drugs/DB15601
    Investigational

    It was granted Orphan Drug Designation by the FDA in October 2019[L11103] and was granted a patent by the European Patent Office in December 2019. … NNZ-2591 (cyclo-L-glycyl-L-2-allylproline)[A189390] is an investigational synthetic analog of cyclic glycine-proline (cGP), a breakdown product of human insulin-like growth factor 1 (IGF-1), that has been

    Categories: Heterocyclic Compounds, 1-RingSynonyms: Cyclo(-L-glycyl-L-2-allylproline), Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-
  8. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  9. Drug

    Niflumic acid

    go.drugbank.com/drugs/DB04552
    Investigational

    Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.

    Categories: Heterocyclic Compounds, 1-Ring, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)
  10. Drug

    Ornoprostil

    go.drugbank.com/drugs/DB20791
    Experimental

    Ornoprostil is a small molecule drug. The usage of the INN stem '-prostil' in the name indicates that Ornoprostil is a anti-ulcer prostaglandin. … Ornoprostil has a monoisotopic molecular weight of 410.27 Da.

    Categories: Prostaglandins E, Prostaglandins E, Synthetic